AGRX - Agile Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development20,92925,62213,365
Selling General and Administrative8,7927,4675,150
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-29,721-33,089-18,515
Income from Continuing Operations
Total Other Income/Expenses Net351-1,141351
Earnings Before Interest and Taxes-29,370-34,230-18,164
Interest Expense2,4462,0771,566
Income Before Tax-31,816-36,307-19,730
Income Tax Expense-3,075-5,972-3,653
Minority Interest---
Net Income From Continuing Ops-28,741-31,371-16,077
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-28,741-30,335-16,077
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-28,741-30,335-16,077